Dennis Oconnor, MD
Family Medicine · Bath, NYNPI 1912935743
Payments from drug & device makers
Across 179 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$400
- Lilly USA, LLC$345
- AstraZeneca$344
- Novo Nordisk$321
- Pfizer$305
- Boehringer Ingelheim$286
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,362100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $400 |
| Lilly USA, LLC | 20 | $345 |
| AstraZeneca | 21 | $344 |
| Novo Nordisk | 16 | $321 |
| Pfizer | 17 | $305 |
| Boehringer Ingelheim | 14 | $286 |
| Johnson & Johnson | 11 | $179 |
| Merck | 8 | $153 |
| Abbott | 5 | $115 |
| Exact Sciences | 4 | $100 |
| Sanofi-aventis U.S. LLC | 6 | $96 |
| GSK | 5 | $90 |
| Teva Pharmaceuticals USA, Inc. | 5 | $85 |
| Astellas Pharma US Inc | 3 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $58 |
| Corcept Therapeutics | 3 | $52 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $37 |
| Inogen, Inc. | 2 | $34 |
| Nabriva Therapeutics, PLC | 2 | $34 |
| Novartis | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Advanced Oxygen Therapy Inc. | 1 | $10 |
How this compares
$3,362 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $155,655 |
| EliquisApixaban | 117 | $133,847 |
| JardianceEmpagliflozin | 94 | $131,117 |
| FarxigaDapagliflozin Propanediol | 60 | $66,021 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 31 | $61,082 |
| XareltoRivaroxaban | 31 | $34,706 |
| TrulicityDulaglutide | 27 | $26,995 |
| InvokanaCanagliflozin | 13 | $17,069 |
| Budesonide ErBudesonide | 11 | $11,959 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $11,625 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $11,356 |
| SteglatroErtugliflozin Pidolate | 12 | $10,181 |
| BrilintaTicagrelor | 11 | $6,314 |
| CreonLipase/Protease/Amylase | 12 | $6,222 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 12 | $5,844 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $321 | $155,655124 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $286 | $142,743107 claims |
| PfizerEliquis | $305 | $133,847117 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $344 | $83,69084 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $96 | $61,08231 claims |
| Johnson & JohnsonXarelto, Invokana | $179 | $51,77544 claims |
| Lilly USA, LLCTrulicity | $345 | $26,99527 claims |
| MerckSteglatro | $153 | $10,18112 claims |
| AbbVieCreon | $400 | $6,22212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.
Other family medicine in Bath
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.